Hester Biosciences rose 2.60% to Rs 2791 after the company announced that it received approval for grant of Rs 60 crore to the company by Biotechnology Industry Research Assistance Council (BIRAC).
In their board meeting on Thursday, the company has approved the execution of grant-in-aid letter agreement for grant in phased manner."Board of Directors, in their Meeting held today, have approved the execution of Grant- in-Aid Letter Agreement for grant of INR 600 million (in phased manner) to the Company by Biotechnology Industry Research Assistance Council (BIRAC), a Government of India Enterprise to support COVID vaccine manufacturing under Mission Covid Suraksha," Hester Biosciences said in a statement on Thursday.
Hester Biosciences is part of Gujarat Covid Vaccine Consortium (GCVC), which comprises Gujarat Biotechnology Research Centre (GBRC) (a Government of Gujarat undertaking), Hester Biosciences and Omnibrx Biotechnologies.
GCVC, in May 2021, signed a pact with Bharat Biotech International towards contract manufacturing for the drug substance for Covaxin. As per the pact, Bharat Biotech will provide the technology for the production of the drug substance for Covaxin, a COVID-19 vaccine. Covaxin is a registered trade mark of Bharat Biotech.
Hester Biosciences will provide the complete infrastructure at its Gujarat plant for the manufacturing of the drug substance. GBRC will act as an advisor and will facilitate the technology transfer from Bharat Biotech. Lastly, Omnibrx Biotechnologies shall act as a technology support partner.
Hester Biosciences is one of India's leading animal healthcare companies and is the second largest poultry vaccine manufacturer in the country.
The company reported 31% fall in consolidated net profit to Rs 8.48 crore on a 2% decline in revenue from operations to Rs 55.69 crore in Q3 FY22 over Q3 FY21.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU